Literature DB >> 25164784

Dietary management in glycogen storage disease type III: what is the evidence?

Terry G J Derks1, G Peter A Smit.   

Abstract

In childhood, GSD type III causes relatively severe fasting intolerance, classically associated with ketotic hypoglycaemia. During follow up, history of (documented) hypoglycaemia, clinical parameters (growth, liver size, motor development, neuromuscular parameters), laboratory parameters (glucose, lactate, ALAT, cholesterol, triglycerides, creatine kinase and ketones) and cardiac parameters all need to be integrated in order to titrate dietary management, for which age-dependent requirements need to be taken into account. Evidence from case studies and small cohort studies in both children and adults with GSD III demonstrate that prevention of hypoglycaemia and maintenance of euglycemia is not sufficient to prevent complications. Moreover, over-treatment with carbohydrates may even be harmful. The ageing cohort of GSD III patients, including the non-traditional clinical presentations in adulthood, raises ‬‬‬new questions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25164784     DOI: 10.1007/s10545-014-9756-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  43 in total

1.  Brain substrate utilisation during acute hypoglycaemia.

Authors:  K Ekberg; E Fernqvist-Forbes; S Nair
Journal:  Diabetologia       Date:  1999-07       Impact factor: 10.122

2.  Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements.

Authors:  A Mendoza; N C Fisher; J Duckett; J McKiernan; M A Preece; A Green; P J McKiernan; G Constantine; E Elias
Journal:  Br J Obstet Gynaecol       Date:  1998-06

3.  Ketosis in hepatic glycogenosis.

Authors:  J Fernandes; N A Pikaar
Journal:  Arch Dis Child       Date:  1972-02       Impact factor: 3.791

4.  Hepatic phosphorylase deficiency. Its differentiation from other hepatic glycogenoses.

Authors:  J Fernandes; J F Koster; W F Grose; N Sorgedrager
Journal:  Arch Dis Child       Date:  1974-03       Impact factor: 3.791

5.  Hexose and protein tolerance tests in children with liver glycogenosis caused by a deficiency of the debranching enzyme system.

Authors:  J Fernandes; J H van de Kamer
Journal:  Pediatrics       Date:  1968-05       Impact factor: 7.124

6.  Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet.

Authors:  Vassili Valayannopoulos; Fanny Bajolle; Jean-Baptiste Arnoux; Sandrine Dubois; Nathalie Sannier; Christiane Baussan; François Petit; Philippe Labrune; Daniel Rabier; Chris Ottolenghi; Anne Vassault; Christine Broissand; Damien Bonnet; Pascale de Lonlay
Journal:  Pediatr Res       Date:  2011-12       Impact factor: 3.756

7.  A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb.

Authors:  M Okubo; A Horinishi; N Nakamura; Y Aoyama; M Hashimoto; Y Endo; T Murase
Journal:  Hum Genet       Date:  1998-01       Impact factor: 4.132

8.  Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy.

Authors:  A E Slonim; R A Coleman; W S Moses
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

Review 9.  Glycogen storage disease in adults.

Authors:  G M Talente; R A Coleman; C Alter; L Baker; B I Brown; R A Cannon; Y T Chen; J F Crigler; P Ferreira; J C Haworth; G E Herman; R M Issenman; J P Keating; R Linde; T F Roe; B Senior; J I Wolfsdorf
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

10.  Glycogen storage disease type III diagnosis and management guidelines.

Authors:  Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

View more
  14 in total

1.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

Review 2.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

3.  Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.

Authors:  Patrice Vidal; Serena Pagliarani; Pasqualina Colella; Helena Costa Verdera; Louisa Jauze; Monika Gjorgjieva; Francesco Puzzo; Solenne Marmier; Fanny Collaud; Marcelo Simon Sola; Severine Charles; Sabrina Lucchiari; Laetitia van Wittenberghe; Alban Vignaud; Bernard Gjata; Isabelle Richard; Pascal Laforet; Edoardo Malfatti; Gilles Mithieux; Fabienne Rajas; Giacomo Pietro Comi; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther       Date:  2017-12-28       Impact factor: 11.454

4.  Normoglycemic Ketonemia as Biochemical Presentation in Ketotic Glycogen Storage Disease.

Authors:  Irene J Hoogeveen; Rixt M van der Ende; Francjan J van Spronsen; Foekje de Boer; M Rebecca Heiner-Fokkema; Terry G J Derks
Journal:  JIMD Rep       Date:  2015-11-03

5.  Hepatic Glycogenoses Among Children-Clinical and Biochemical Characterization: Single-Center Study.

Authors:  Sophy Korula; Sumita Danda; Praveen G Paul; Sarah Mathai; Anna Simon
Journal:  J Clin Exp Hepatol       Date:  2019-07-25

6.  Facial Dysmorphic Features in a Patient With Nonketotic Hypoglycemia and a Pathogenic Variant in the AKT2 Gene.

Authors:  Maria Fernanda Ochoa Molina; Helena Poggi; Valeria De Toro; Carolina Mendoza; Khalid Hussain
Journal:  AACE Clin Case Rep       Date:  2021-11-27

Review 7.  Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.

Authors:  Terry G J Derks; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2015-01-30       Impact factor: 4.982

8.  Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.

Authors:  Christiaan P Sentner; Irene J Hoogeveen; David A Weinstein; René Santer; Elaine Murphy; Patrick J McKiernan; Ulrike Steuerwald; Nicholas J Beauchamp; Joanna Taybert; Pascal Laforêt; François M Petit; Aurélie Hubert; Philippe Labrune; G Peter A Smit; Terry G J Derks
Journal:  J Inherit Metab Dis       Date:  2016-04-22       Impact factor: 4.982

Review 9.  Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver.

Authors:  Pankaj Puri; Radha K Dhiman; Sunil Taneja; Puneeta Tandon; Manuela Merli; Anil C Anand; Anil Arora; Subrat K Acharya; Jaya Benjamin; Yogesh K Chawla; Sunil Dadhich; Ajay Duseja; C E Eapan; Amit Goel; Naveen Kalra; Dharmesh Kapoor; Ashish Kumar; Kaushal Madan; Aabha Nagral; Gaurav Pandey; Padaki N Rao; Sanjiv Saigal; Neeraj Saraf; Vivek A Saraswat; Anoop Saraya; Shiv K Sarin; Praveen Sharma; Akash Shukla; Sandeep S Sidhu; Namrata Singh; Shivaram P Singh; Anshu Srivastava; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-10-01

10.  Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.

Authors:  Serena Pagliarani; Sabrina Lucchiari; Gianna Ulzi; Michela Ripolone; Raffaella Violano; Francesco Fortunato; Andreina Bordoni; Stefania Corti; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-01       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.